Separate terms with OR to return results that match either term.
 
Clear All
10,000 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name (Descending) Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
72237-0101-05 72237-0101 Selinexor XPOVIO 20.0 mg/1 Chemotherapy Enzyme Inhibitor XPO1 Oral July 10, 2019 In Use
72237-0101-06 72237-0101 Selinexor XPOVIO 20.0 mg/1 Chemotherapy Enzyme Inhibitor XPO1 Oral June 22, 2020 In Use
72237-0101-07 72237-0101 Selinexor XPOVIO 20.0 mg/1 Chemotherapy Enzyme Inhibitor XPO1 Oral June 22, 2020 In Use
72237-0102-02 72237-0102 selinexor XPOVIO 40.0 mg/1 Chemotherapy Enzyme Inhibitor XPO1 Oral May 19, 2021 In Use
72237-0102-06 72237-0102 selinexor XPOVIO 40.0 mg/1 Chemotherapy Enzyme Inhibitor XPO1 Oral May 19, 2021 In Use
72237-0102-07 72237-0102 selinexor XPOVIO 40.0 mg/1 Chemotherapy Enzyme Inhibitor XPO1 Oral May 19, 2021 In Use
72237-0103-05 72237-0103 selinexor XPOVIO 50.0 mg/1 Chemotherapy Enzyme Inhibitor XPO1 Oral May 19, 2021 In Use
72237-0104-01 72237-0104 selinexor XPOVIO 60.0 mg/1 Chemotherapy Enzyme Inhibitor XPO1 Oral May 19, 2021 In Use
55513-0730-01 55513-0730 Denosumab XGEVA 120.0 mg/1.7mL Immunotherapy Monoclonal Antibody RANKL Subcutaneous Nov. 18, 2010 In Use
00006-5331-01 00006-5331 Belzutifan WELIREG 40.0 mg/1 Chemotherapy Miscellaneous Agent HIF-2 alpha Oral Aug. 13, 2021 In Use
00006-5331-58 00006-5331 Belzutifan WELIREG 40.0 mg/1 Chemotherapy Miscellaneous Agent HIF-2 alpha Oral June 21, 2023 In Use
00006-5331-59 00006-5331 Belzutifan WELIREG 40.0 mg/1 Chemotherapy Miscellaneous Agent HIF-2 alpha Oral June 21, 2023 In Use
68727-0745-01 68727-0745 (daunorubicin and cytarabine) liposome Vyxeos 100.0 mg/20mL, 44.0 mg/20mL Chemotherapy Antitumor Antibiotic & Antimetabolite Anthracycline & Pyrimidine Analog Intravenous Aug. 3, 2017 In Use
68727-0745-02 68727-0745 (daunorubicin and cytarabine) liposome Vyxeos 100.0 mg/20mL, 44.0 mg/20mL Chemotherapy Antitumor Antibiotic & Antimetabolite Anthracycline & Pyrimidine Analog Intravenous Aug. 3, 2017 In Use
68727-0745-05 68727-0745 (daunorubicin and cytarabine) liposome Vyxeos 100.0 mg/20mL, 44.0 mg/20mL Chemotherapy Antitumor Antibiotic & Antimetabolite Anthracycline & Pyrimidine Analog Intravenous Aug. 3, 2017 In Use
00173-0804-09 00173-0804 Pazopanib Hydrochloride Votrient 200.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FGF, PDGFR, KIT, Lck, FMS Oral Oct. 19, 2009 June 30, 2017 No Longer Used
00173-0804-61 00173-0804 Pazopanib Hydrochloride Votrient 200.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FGF, PDGFR, KIT, Lck, FMS Oral Oct. 19, 2009 Nov. 30, 2017 No Longer Used
00078-0670-66 00078-0670 Pazopanib Hydrochloride Votrient 200.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor VEGFR, FGF, PDGFR, KIT, Lck, FMS Oral July 12, 2016 Oct. 31, 2024 In Use
50633-0210-11 50633-0210 Glucarpidase Voraxaze 1000.0 [USP'U]/1 Ancillary Therapy Chemoprotective Antidote Intravenous April 1, 2012 In Use
72482-0100-12 72482-0100 Pacritinib Vonjo 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor JAK2, FLT3 Oral Feb. 28, 2022 In Use
00069-0197-30 00069-0197 dacomitinib Vizimpro 15.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Oct. 4, 2018 In Use
00069-2299-30 00069-2299 dacomitinib Vizimpro 45.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Oct. 4, 2018 In Use
00069-1198-30 00069-1198 dacomitinib Vizimpro 30.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Oct. 4, 2018 In Use
63539-0197-90 63539-0197 Dacomitinib Vizimpro 15.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Feb. 1, 2019 In Use
69468-0151-04 69468-0151 Uridine Triacetate Vistogard 951.0 mg/g Ancillary Therapy Chemoprotective Antidote Oral March 1, 2016 In Use
69468-0151-10 69468-0151 Uridine Triacetate Vistogard 951.0 mg/g Ancillary Therapy Chemoprotective Antidote Oral March 1, 2016 In Use
69468-0151-20 69468-0151 Uridine Triacetate Vistogard 951.0 mg/g Ancillary Therapy Chemoprotective Antidote Oral March 1, 2016 In Use
00008-0045-01 00008-0045 Vinorelbine tartrate Vinorelbine tartrate 10.0 mg/mL Chemotherapy Antimitotic Agent Vinca Alkaloid Intravenous Feb. 13, 2008 In Use
00008-0045-02 00008-0045 Vinorelbine tartrate Vinorelbine tartrate 10.0 mg/mL Chemotherapy Antimitotic Agent Vinca Alkaloid Intravenous Feb. 13, 2008 In Use
66758-0045-01 66758-0045 Vinorelbine tartrate Vinorelbine tartrate 10.0 mg/mL Chemotherapy Antimitotic Agent Vinca Alkaloid Intravenous Feb. 13, 2008 Oct. 6, 2014 No Longer Used
66758-0045-02 66758-0045 Vinorelbine tartrate Vinorelbine tartrate 10.0 mg/mL Chemotherapy Antimitotic Agent Vinca Alkaloid Intravenous Feb. 13, 2008 Oct. 6, 2014 No Longer Used
00069-0099-01 00069-0099 Vinorelbine Vinorelbine 10.0 mg/mL Chemotherapy Antimitotic Agent Vinca Alkaloid Intravenous Sept. 1, 2012 Aug. 31, 2016 No Longer Used
00069-0103-03 00069-0103 Vinorelbine Vinorelbine 10.0 mg/mL Chemotherapy Antimitotic Agent Vinca Alkaloid Intravenous Sept. 1, 2012 Aug. 31, 2016 No Longer Used
00069-0205-10 00069-0205 Vinorelbine Vinorelbine 10.0 mg/mL Chemotherapy Antimitotic Agent Vinca Alkaloid Intravenous Sept. 1, 2012 Aug. 31, 2016 No Longer Used
00069-0205-50 00069-0205 Vinorelbine Vinorelbine 10.0 mg/mL Chemotherapy Antimitotic Agent Vinca Alkaloid Intravenous Sept. 1, 2012 Aug. 31, 2016 No Longer Used
00703-4182-01 00703-4182 Vinorelbine Vinorelbine 10.0 mg/mL Chemotherapy Antimitotic Agent Vinca Alkaloid Intravenous March 1, 2003 Nov. 30, 2012 No Longer Used
00703-4182-91 00703-4182 Vinorelbine Vinorelbine 10.0 mg/mL Chemotherapy Antimitotic Agent Vinca Alkaloid Intravenous March 1, 2003 May 31, 2012 No Longer Used
00703-4183-01 00703-4183 Vinorelbine Vinorelbine 50.0 mg/5mL Chemotherapy Antimitotic Agent Vinca Alkaloid Intravenous March 1, 2003 April 30, 2013 No Longer Used
00703-4183-91 00703-4183 Vinorelbine Vinorelbine 50.0 mg/5mL Chemotherapy Antimitotic Agent Vinca Alkaloid Intravenous March 1, 2003 Dec. 31, 2012 No Longer Used
25021-0204-01 25021-0204 Vinorelbine Vinorelbine 10.0 mg/mL Chemotherapy Antimitotic Agent Vinca Alkaloid Intravenous Sept. 15, 2014 In Use
25021-0204-05 25021-0204 Vinorelbine Vinorelbine 10.0 mg/mL Chemotherapy Antimitotic Agent Vinca Alkaloid Intravenous Sept. 15, 2014 In Use
45963-0607-55 45963-0607 Vinorelbine Vinorelbine 10.0 mg/mL, 10.0 mg/mL Chemotherapy Antimitotic Agent Vinca Alkaloid Intravenous March 1, 2015 In Use
45963-0607-56 45963-0607 Vinorelbine Vinorelbine 10.0 mg/mL, 10.0 mg/mL Chemotherapy Antimitotic Agent Vinca Alkaloid Intravenous March 1, 2015 In Use
67457-0431-11 67457-0431 Vinorelbine Vinorelbine 10.0 mg/mL, 10.0 mg/mL Chemotherapy Antimitotic Agent Vinca Alkaloid Intravenous Sept. 1, 2012 Aug. 31, 2016 No Longer Used
67457-0479-53 67457-0479 Vinorelbine Vinorelbine 10.0 mg/mL, 10.0 mg/mL Chemotherapy Antimitotic Agent Vinca Alkaloid Intravenous Sept. 1, 2012 Aug. 31, 2016 No Longer Used
67457-0481-01 67457-0481 Vinorelbine Vinorelbine 10.0 mg/mL, 10.0 mg/mL Chemotherapy Antimitotic Agent Vinca Alkaloid Intravenous Sept. 1, 2012 Aug. 31, 2016 No Longer Used
67457-0482-05 67457-0482 Vinorelbine Vinorelbine 10.0 mg/mL Chemotherapy Antimitotic Agent Vinca Alkaloid Intravenous Sept. 1, 2012 Aug. 31, 2016 No Longer Used
50742-0420-01 50742-0420 Vinorelbine Vinorelbine 10.0 mg/mL Chemotherapy Antimitotic Agent Vinca Alkaloid Intravenous Aug. 8, 2019 In Use
50742-0427-05 50742-0427 Vinorelbine Vinorelbine 50.0 mg/5mL Chemotherapy Antimitotic Agent Vinca Alkaloid Intravenous Aug. 8, 2019 In Use
61703-0341-06 61703-0341 Vinorelbine Vinorelbine 10.0 mg/mL Chemotherapy Antimitotic Agent Vinca Alkaloid Intravenous April 9, 2007 Oct. 31, 2017 No Longer Used

Found 10,000 results in 6 milliseconds — Export these results